Compare $MDXG vs $NVCT | Chartloom

Compare

$MDXG vs $NVCT

MiMedx Group Inc · Nuvectis Pharma Inc

MDXG

MiMedx Group Inc

NVCT

Nuvectis Pharma Inc

Compare $MDXG vs $NVCT

Comparing MiMedx Group Inc and Nuvectis Pharma Inc

MDXGMiMedx Group Inc

NVCTNuvectis Pharma Inc

MDXGMiMedx Group Inc

Market cap

$681M

P/E (TTM)

110.63x

Forward P/E (NTM)

130.81x

Forward P/S (NTM)

2.16x

Rev growth (TTM)

-2.4%

YTD performance

-27.9%

52W performance

-34.2%

FCF yield

6.5%

NVCTNuvectis Pharma Inc

Market cap

$666M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

148.2%

52W performance

239.0%

FCF yield

-2.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MDXG

NVCT

Detailed metrics comparison

MDXG

MiMedx Group Inc

NVCT

Nuvectis Pharma Inc

Market Cap

MDXG$681M

NVCT$666M

Enterprise Value

MDXG$562M

NVCT$644M

Price

MDXG$4.67

NVCT$21.12

P/E Ratio

MDXG110.63x

NVCTN/A

P/S Ratio

MDXG1.92x

NVCT0.00x

EV/Sales

MDXG1.58x

NVCT0.00x

EV/EBITDA

MDXG27.54x

NVCT0.00x

P/B Ratio

MDXG3.10x

NVCT78.79x

P/FCF Ratio

MDXG15.32x

NVCTN/A

EV/FCF

MDXG12.65x

NVCT-33.00x

PEG Ratio

MDXGN/A

NVCTN/A

Forward P/E (NTM)

MDXG130.81x

NVCTN/A

Forward P/S (NTM)

MDXG2.16x

NVCTN/A

Revenue (TTM)

MDXG$355M

NVCT$0

Revenue Growth (YoY)

MDXG-2.4%

NVCTN/A

Forward Rev Growth

MDXG22.1%

NVCT0.0%

Gross Margin (TTM)

MDXG78.8%

NVCT0.0%

Operating Margin (TTM)

MDXG2.5%

NVCT0.0%

EBITDA Margin (TTM)

MDXG5.7%

NVCT0.0%

Net Margin (TTM)

MDXG1.8%

NVCT0.0%

FCF Margin (TTM)

MDXG12.5%

NVCTN/A

Net Income (TTM)

MDXG$6M

NVCT$-30M

FCF (TTM)

MDXG$44M

NVCT$-20M

EPS (TTM)

MDXG$0.04

NVCT-$1.29

ROE (TTM)

MDXG2.6%

NVCT-16947.0%

ROA (TTM)

MDXG2.0%

NVCT-9680.0%

ROIC (TTM)

MDXG2.4%

NVCT-16947.0%

Cash

MDXG$136M

NVCT$22M

Debt

MDXG$17M

NVCT$0

Net Cash/Debt

MDXG$119M

NVCT$22M

Current Ratio (TTM)

MDXG5.33x

NVCT1.68x

Quick Ratio (TTM)

MDXG4.79x

NVCT1.68x

Debt/Equity (TTM)

MDXG0.08x

NVCT0.00x

Debt/Assets (TTM)

MDXG0.0%

NVCT0.0%

Interest Coverage (TTM)

MDXGN/A

NVCTN/A

Net Debt/EBITDA (TTM)

MDXG0.00x

NVCT0.00x

Beta

MDXG1.20

NVCT-0.23

52W Performance

MDXG-34.2%

NVCT239.0%

YTD Performance

MDXG-27.9%

NVCT148.2%

% from 52W High

MDXG-41.4%

NVCT-27.9%

% from 52W Low

MDXG54.1%

NVCT280.5%

Asset Turnover (TTM)

MDXG1.14x

NVCT0.00x

FCF Yield (TTM)

MDXG6.5%

NVCT-2.9%

Earnings Yield (TTM)

MDXG0.9%

NVCT-4.5%

Dividend Yield (TTM)

MDXGN/A

NVCTN/A

Rule of 40

MDXG10.1

NVCT0.0

EV/GP/RG

MDXG0.09

NVCTN/A

Ticker research

View MDXG research View NVCT research

Metric	MDXG MiMedx Group Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$681M	$666M
Enterprise Value	$562M	$644M
Price	$4.67	$21.12
P/E Ratio	110.63x	N/A
P/S Ratio	1.92x	0.00x
EV/Sales	1.58x	0.00x
EV/EBITDA	27.54x	0.00x
P/B Ratio	3.10x	78.79x
P/FCF Ratio	15.32x	N/A
EV/FCF	12.65x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	130.81x	N/A
Forward P/S (NTM)	2.16x	N/A
Revenue & Growth
Revenue (TTM)	$355M	$0
Revenue Growth (YoY)	-2.4%	N/A
Forward Rev Growth	22.1%	0.0%
Profitability
Gross Margin (TTM)	78.8%	0.0%
Operating Margin (TTM)	2.5%	0.0%
EBITDA Margin (TTM)	5.7%	0.0%
Net Margin (TTM)	1.8%	0.0%
FCF Margin (TTM)	12.5%	N/A
Net Income (TTM)	$6M	$-30M
FCF (TTM)	$44M	$-20M
EPS (TTM)	$0.04	-$1.29
ROE (TTM)	2.6%	-16947.0%
ROA (TTM)	2.0%	-9680.0%
ROIC (TTM)	2.4%	-16947.0%
Financial Health
Cash	$136M	$22M
Debt	$17M	$0
Net Cash/Debt	$119M	$22M
Current Ratio (TTM)	5.33x	1.68x
Quick Ratio (TTM)	4.79x	1.68x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	-0.23
52W Performance	-34.2%	239.0%
YTD Performance	-27.9%	148.2%
% from 52W High	-41.4%	-27.9%
% from 52W Low	54.1%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.00x
FCF Yield (TTM)	6.5%	-2.9%
Earnings Yield (TTM)	0.9%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	10.1	0.0
EV/GP/RG	0.09	N/A
Ticker research	View MDXG research	View NVCT research

Valuation

P/E Ratio

MDXG

110.63x

P/S Ratio

NVCT

0.00x

MDXG

1.92x

EV/FCF

NVCT

-33.00x

MDXG

12.65x

Growth & revenue

Revenue Growth TTM

MDXG

-2.4%

Forward Revenue Growth

MDXG

22.1%

NVCT

0.0%

Profitability & performance

Gross Margin

MDXG

78.8%

NVCT

0.0%

ROE

MDXG

2.6%

NVCT

-16947.0%

FCF Yield %

MDXG

6.5%

NVCT

-2.9%

52-Week Performance

NVCT

239.0%

MDXG

-34.2%

Detailed metrics comparison

MDXG

MiMedx Group Inc

NVCT

Nuvectis Pharma Inc

Market Cap

MDXG$681M

NVCT$666M

Enterprise Value

MDXG$562M

NVCT$644M

Price

MDXG$4.67

NVCT$21.12

P/E Ratio

MDXG110.63x

NVCTN/A

P/S Ratio

MDXG1.92x

NVCT0.00x

EV/Sales

MDXG1.58x

NVCT0.00x

EV/EBITDA

MDXG27.54x

NVCT0.00x

P/B Ratio

MDXG3.10x

NVCT78.79x

P/FCF Ratio

MDXG15.32x

NVCTN/A

EV/FCF

MDXG12.65x

NVCT-33.00x

PEG Ratio

MDXGN/A

NVCTN/A

Forward P/E (NTM)

MDXG130.81x

NVCTN/A

Forward P/S (NTM)

MDXG2.16x

NVCTN/A

Revenue (TTM)

MDXG$355M

NVCT$0

Revenue Growth (YoY)

MDXG-2.4%

NVCTN/A

Forward Rev Growth

MDXG22.1%

NVCT0.0%

Gross Margin (TTM)

MDXG78.8%

NVCT0.0%

Operating Margin (TTM)

MDXG2.5%

NVCT0.0%

EBITDA Margin (TTM)

MDXG5.7%

NVCT0.0%

Net Margin (TTM)

MDXG1.8%

NVCT0.0%

FCF Margin (TTM)

MDXG12.5%

NVCTN/A

Net Income (TTM)

MDXG$6M

NVCT$-30M

FCF (TTM)

MDXG$44M

NVCT$-20M

EPS (TTM)

MDXG$0.04

NVCT-$1.29

ROE (TTM)

MDXG2.6%

NVCT-16947.0%

ROA (TTM)

MDXG2.0%

NVCT-9680.0%

ROIC (TTM)

MDXG2.4%

NVCT-16947.0%

Cash

MDXG$136M

NVCT$22M

Debt

MDXG$17M

NVCT$0

Net Cash/Debt

MDXG$119M

NVCT$22M

Current Ratio (TTM)

MDXG5.33x

NVCT1.68x

Quick Ratio (TTM)

MDXG4.79x

NVCT1.68x

Debt/Equity (TTM)

MDXG0.08x

NVCT0.00x

Debt/Assets (TTM)

MDXG0.0%

NVCT0.0%

Interest Coverage (TTM)

MDXGN/A

NVCTN/A

Net Debt/EBITDA (TTM)

MDXG0.00x

NVCT0.00x

Beta

MDXG1.20

NVCT-0.23

52W Performance

MDXG-34.2%

NVCT239.0%

YTD Performance

MDXG-27.9%

NVCT148.2%

% from 52W High

MDXG-41.4%

NVCT-27.9%

% from 52W Low

MDXG54.1%

NVCT280.5%

Asset Turnover (TTM)

MDXG1.14x

NVCT0.00x

FCF Yield (TTM)

MDXG6.5%

NVCT-2.9%

Earnings Yield (TTM)

MDXG0.9%

NVCT-4.5%

Dividend Yield (TTM)

MDXGN/A

NVCTN/A

Rule of 40

MDXG10.1

NVCT0.0

EV/GP/RG

MDXG0.09

NVCTN/A

Ticker research

View MDXG research View NVCT research

Metric	MDXG MiMedx Group Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$681M	$666M
Enterprise Value	$562M	$644M
Price	$4.67	$21.12
P/E Ratio	110.63x	N/A
P/S Ratio	1.92x	0.00x
EV/Sales	1.58x	0.00x
EV/EBITDA	27.54x	0.00x
P/B Ratio	3.10x	78.79x
P/FCF Ratio	15.32x	N/A
EV/FCF	12.65x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	130.81x	N/A
Forward P/S (NTM)	2.16x	N/A
Revenue & Growth
Revenue (TTM)	$355M	$0
Revenue Growth (YoY)	-2.4%	N/A
Forward Rev Growth	22.1%	0.0%
Profitability
Gross Margin (TTM)	78.8%	0.0%
Operating Margin (TTM)	2.5%	0.0%
EBITDA Margin (TTM)	5.7%	0.0%
Net Margin (TTM)	1.8%	0.0%
FCF Margin (TTM)	12.5%	N/A
Net Income (TTM)	$6M	$-30M
FCF (TTM)	$44M	$-20M
EPS (TTM)	$0.04	-$1.29
ROE (TTM)	2.6%	-16947.0%
ROA (TTM)	2.0%	-9680.0%
ROIC (TTM)	2.4%	-16947.0%
Financial Health
Cash	$136M	$22M
Debt	$17M	$0
Net Cash/Debt	$119M	$22M
Current Ratio (TTM)	5.33x	1.68x
Quick Ratio (TTM)	4.79x	1.68x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	-0.23
52W Performance	-34.2%	239.0%
YTD Performance	-27.9%	148.2%
% from 52W High	-41.4%	-27.9%
% from 52W Low	54.1%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.00x
FCF Yield (TTM)	6.5%	-2.9%
Earnings Yield (TTM)	0.9%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	10.1	0.0
EV/GP/RG	0.09	N/A
Ticker research	View MDXG research	View NVCT research